Search

Your search keyword '"Petit, Anna"' showing total 21 results
Start Over Author "Petit, Anna" Publication Year Range Last 3 years
21 results on '"Petit, Anna"'

1. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact

Author

Garcia-Tejedor, Amparo, Falo, Catalina, Fernandez-Gonzalez, Sergi, Laplana, Maria, Gil-Gil, Miguel, Soler-Monso, Teresa, Martinez-Perez, Evelyn, Calvo, Iris, Calpelo, Hugo, Bajen, Maria-Teresa, Benitez, Ana, Ortega, Raul, Petit, Anna, Guma, Anna, Campos, Miriam, Stradella, Agostina, Lopez-Ojeda, Ana, Ponce, Jordi, Pla, Maria J., and Pernas, Sonia

Published
2023
Full Text
View/download PDF

3. RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

Author

Ciscar, Marina, Trinidad, Eva M, Perez‐Chacon, Gema, Alsaleem, Mansour, Jimenez, Maria, Jimenez‐Santos, Maria J, Perez‐Montoyo, Hector, Sanz‐Moreno, Adrian, Vethencourt, Andrea, Toss, Michael, Petit, Anna, Soler‐Monso, Maria T, Lopez, Victor, Gomez‐Miragaya, Jorge, Gomez‐Aleza, Clara, Dobrolecki, Lacey E, Lewis, Michael T, Bruna, Alejandra, Mouron, Silvana, Quintela‐Fandino, Miguel, Al‐Shahrour, Fatima, Martinez‐Aranda, Antonio, Sierra, Angels, Green, Andrew R, Rakha, Emad, and Gonzalez‐Suarez, Eva

Published
2023
Full Text
View/download PDF

5. Modification of BRCA1-associated breast cancer risk by HMMR overexpression

Author

Mateo, Francesca, He, Zhengcheng, Mei, Lin, de Garibay, Gorka Ruiz, Herranz, Carmen, García, Nadia, Lorentzian, Amanda, Baiges, Alexandra, Blommaert, Eline, Gómez, Antonio, Mirallas, Oriol, Garrido-Utrilla, Anna, Palomero, Luis, Espín, Roderic, Extremera, Ana I., Soler-Monsó, M. Teresa, Petit, Anna, Li, Rong, Brunet, Joan, Chen, Ke, Tan, Susanna, Eaves, Connie J., McCloskey, Curtis, Hakem, Razq, Khokha, Rama, Lange, Philipp F., Lázaro, Conxi, Maxwell, Christopher A., and Pujana, Miquel Angel

Published
2022
Full Text
View/download PDF

6. Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.

Author

Vethencourt, Andrea, primary, Trinidad, Eva M., additional, Dorca, Eduard, additional, Petit, Anna, additional, Soler-Monsó, M. Teresa, additional, Ciscar, Marina, additional, Barranco, Alexandra, additional, Pérez-Chacón, Gema, additional, Jimenez, María, additional, Gomez-Aleza, Clara, additional, Purqueras, Elvira, additional, Hernández-Jiménez, Enrique, additional, Urruticoechea, Ander, additional, Morilla, Idoia, additional, Cachinero, Isaac, additional, García-Tejedor, Amparo, additional, Gil-Gil, Miguel, additional, Pernas, Sonia, additional, Falo, Catalina, additional, and Gonzalez-Suarez, Eva, additional

Published
2024
Full Text
View/download PDF

7. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

Author

Sanz-Moreno, Adrián, Palomeras, Sonia, Pedersen, Kim, Morancho, Beatriz, Pascual, Tomas, Galván, Patricia, Benítez, Sandra, Gomez-Miragaya, Jorge, Ciscar, Marina, Jimenez, Maria, Pernas, Sonia, Petit, Anna, Soler-Monsó, María Teresa, Viñas, Gemma, Alsaleem, Mansour, Rakha, Emad A., Green, Andrew R., Santamaria, Patricia G., Mulder, Celine, Lemeer, Simone, Arribas, Joaquin, Prat, Aleix, Puig, Teresa, and Gonzalez-Suarez, Eva

Published
2021
Full Text
View/download PDF

8. Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial)

Author

Garcia-Tejedor, Amparo, primary, Ortega-Exposito, Carlos, additional, Salinas, Sira, additional, Luzardo-González, Ana, additional, Falo, Catalina, additional, Martinez-Pérez, Evelyn, additional, Pérez-Montero, Héctor, additional, Soler-Monsó, M. Teresa, additional, Bajen, Maria-Teresa, additional, Benitez, Ana, additional, Ortega, Raul, additional, Petit, Anna, additional, Guma, Anna, additional, Campos, Miriam, additional, Plà, Maria J., additional, Pernas, Sonia, additional, Peñafiel, Judith, additional, Yeste, Carlos, additional, Gil-Gil, Miguel, additional, Guedea, Ferran, additional, Ponce, Jordi, additional, and Laplana, Maria, additional

Published
2023
Full Text
View/download PDF

10. Thyroid cells from normal and autoimmune thyroid glands suppress T lymphocytes proliferation upon contact revealing a new regulatory inhibitory type of interaction independent of PD1/PDL1

Author

Álvarez-Sierra, Daniel, primary, Sánchez-Gaona, Nerea, additional, Cruz Cobo, María, additional, Escriche, Alba, additional, Abad, María, additional, Gómez-Brey, Aroa, additional, Bello, Irene, additional, Caubet, Enric, additional, González, Óscar, additional, Zafón, Carles, additional, Iglesias, Carmela, additional, Moreno, Pablo, additional, Petit, Anna, additional, Fernández-Sanmartín, Marco Antonio, additional, Martínez-Gallo, Mónica, additional, and Pujol-Borrell, Ricardo, additional

Published
2023
Full Text
View/download PDF

11. Supplementary Figure S1 from Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

Author

Gómez-Miragaya, Jorge, primary, Díaz-Navarro, Ander, primary, Tonda, Raul, primary, Beltran, Sergi, primary, Palomero, Luis, primary, Palafox, Marta, primary, Dobrolecki, Lacey E., primary, Huang, Chen, primary, Vasaikar, Suhas, primary, Zhang, Bing, primary, Wulf, Gerburg M., primary, Collado-Sole, Alejandro, primary, Trinidad, Eva M., primary, Muñoz, Purificación, primary, Paré, Laia, primary, Prat, Aleix, primary, Bruna, Alejandra, primary, Caldas, Carlos, primary, Arribas, Joaquín, primary, Soler-Monso, María Teresa, primary, Petit, Anna, primary, Balmaña, Judith, primary, Cruz, Cristina, primary, Serra, Violeta, primary, Pujana, Miguel Angel, primary, Lewis, Michael T., primary, Puente, Xose S., primary, and González-Suárez, Eva, primary

Published
2023
Full Text
View/download PDF

12. RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

Author

Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Susan G. Komen Foundation, Generalitat de Catalunya, European Research Council, Amgen, Ministerio de Sanidad y Consumo (España), National Institutes of Health (US), Cancer Prevention and Research Institute of Texas, Ciscar, Marina, Trinidad, Eva M., Pérez-Chacón, Gema, Alsaleem, Mansour, Jiménez, María, Jiménez-Santos, María J., Pérez-Montoyo, Héctor, Sanz-Moreno, Adrián, Vethencourt, Andrea, Toss, Michael, Petit, Anna, Soler-Monso, María T., López, Victor, Gómez-Miragaya, Jorge, Gómez-Aleza, Clara, Dobrolecki, Lacey E., Lewis, Michael T., Bruna, Alejandra, Mouron, Silvana, Quintela-Fandino, Miguel, Al-Shahrour, Fátima, Martínez-Aranda, Antonio, Sierra, Angels, Green, Andrew R., Rakha, Emad, González-Suarez, Eva, Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Susan G. Komen Foundation, Generalitat de Catalunya, European Research Council, Amgen, Ministerio de Sanidad y Consumo (España), National Institutes of Health (US), Cancer Prevention and Research Institute of Texas, Ciscar, Marina, Trinidad, Eva M., Pérez-Chacón, Gema, Alsaleem, Mansour, Jiménez, María, Jiménez-Santos, María J., Pérez-Montoyo, Héctor, Sanz-Moreno, Adrián, Vethencourt, Andrea, Toss, Michael, Petit, Anna, Soler-Monso, María T., López, Victor, Gómez-Miragaya, Jorge, Gómez-Aleza, Clara, Dobrolecki, Lacey E., Lewis, Michael T., Bruna, Alejandra, Mouron, Silvana, Quintela-Fandino, Miguel, Al-Shahrour, Fátima, Martínez-Aranda, Antonio, Sierra, Angels, Green, Andrew R., Rakha, Emad, and González-Suarez, Eva

Abstract

Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor‐negative, ER−) from four independent cohorts. RANK protein expression was more frequent in ER− tumors, where it associated with poor outcome and poor response to chemotherapy. In ER− breast cancer patient‐derived orthoxenografts (PDXs), RANKL inhibition reduced tumor cell proliferation and stemness, regulated tumor immunity and metabolism, and improved response to chemotherapy. Intriguingly, tumor RANK protein expression associated with poor prognosis in postmenopausal breast cancer patients, activation of NFKB signaling, and modulation of immune and metabolic pathways, suggesting that RANK signaling increases after menopause. Our results demonstrate that RANK protein expression is an independent biomarker of poor prognosis in postmenopausal and ER− breast cancer patients and support the therapeutic benefit of RANK pathway inhibitors, such as denosumab, in breast cancer patients with RANK+ ER− tumors after menopause.

Published
2023

13. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/ HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.

Author

Garcia-Tejedor, Amparo, primary, Fernandez-Gonzalez, Sergi, additional, Laplana, Maria, additional, Gil-Gil, Miguel, additional, Martinez, Evelyn, additional, Calvo, Iris, additional, Calpelo, Hugo, additional, Ortega, Raul, additional, Petit, Anna, additional, Guma, Anna, additional, Campos, Miriam, additional, Stradella, Agostina, additional, and López-Ojeda, Ana, additional

Published
2023
Full Text
View/download PDF

14. Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response

Author

Lejeune, Marylène, primary, Reverté, Laia, additional, Sauras, Esther, additional, Gallardo, Noèlia, additional, Bosch, Ramon, additional, Roso, Albert, additional, Petit, Anna, additional, Peg, Vicente, additional, Riu, Francisco, additional, García-Fontgivell, Joan, additional, Ibáñez, José, additional, Relea, Fernanda, additional, Vieites, Begoña, additional, Bor, Catherine, additional, de la Cruz-Merino, Luis, additional, Arenas, Meritxell, additional, Rodriguez, Valerie, additional, Galera, Juana, additional, Korzynska, Anna, additional, Belhomme, Philippe, additional, Plancoulaine, Benoît, additional, Álvaro, Tomás, additional, and López, Carlos, additional

Published
2023
Full Text
View/download PDF

15. Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.

Author

Lejeune, Marylène, Reverté, Laia, Gallardo, Noèlia, Sauras, Esther, Bosch, Ramon, Mata, Daniel, Roso, Albert, Petit, Anna, Peg, Vicente, Riu, Francisco, García-Fontgivell, Joan, Relea, Fernanda, Vieites, Begoña, de la Cruz-Merino, Luis, Arenas, Meritxell, Rodriguez, Valeri, Galera, Juana, Korzynska, Anna, Plancoulaine, Benoît, and Álvaro, Tomás

Subjects
TRIPLE-negative breast cancer, NEOADJUVANT chemotherapy, CANCER patients, PROGNOSIS, REGULATORY T cells, BREAST
Abstract

Triple-negative breast cancer (TNBC) is particularly challenging due to the weak or absent response to therapeutics and its poor prognosis. The effectiveness of neoadjuvant chemotherapy (NAC) response is strongly influenced by changes in elements of the tumor microenvironment (TME). This work aimed to characterize the residual TME composition in 96 TNBC patients using immunohistochemistry and in situ hybridization techniques and evaluate its prognostic implications for partial responders vs. non-responders. Compared with non-responders, partial responders containing higher levels of CD83+ mature dendritic cells, FOXP3+ regulatory T cells, and IL-15 expression but lower CD138+ cell concentration exhibited better OS and RFS. However, along with tumor diameter and positive nodal status at diagnosis, matrix metalloproteinase-9 (MMP-9) expression in the residual TME was identified as an independent factor associated with the impaired response to NAC. This study yields new insights into the key components of the residual tumor bed, such as MMP-9, which is strictly associated with the lack of a pathological response to NAC. This knowledge might help early identification of TNBC patients less likely to respond to NAC and allow the establishment of new therapeutic targets. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Lymphocytic Thyroiditis Transcriptomic Profiles Support the Role of Checkpoint Pathways and B Cells in Pathogenesis

Author

Álvarez-Sierra, Daniel, primary, Marín-Sánchez, Ana, additional, Gómez-Brey, Aroa, additional, Bello, Irene, additional, Caubet, Enric, additional, Moreno-Llorente, Pablo, additional, Petit, Anna, additional, Zafón, Carles, additional, Iglesias, Carmela, additional, González, Óscar, additional, and Pujol-Borrell, Ricardo, additional

Published
2022
Full Text
View/download PDF

17. Abstract P2-08-10: First results of the randomized window of opportunity clinical trial D-Biomark: Immunomodulatory effect of denosumab in early breast cancer

Author

Vethencourt, Andrea, primary, Trinidad, Eva M, additional, Petit, Anna, additional, Soler-Monsó, María T, additional, Aleza, Clara Gómez, additional, Urruticochea, Ander, additional, García-Tejedor, Amparo, additional, Martinez, Anna Gumà, additional, Obadia, Veronica, additional, Vazquez, Silvia, additional, Villanueva, Rafael, additional, Fernánez, Adela, additional, Cejuela, Monica, additional, Penabad, Sabela Recalde, additional, Stradella, Agostina, additional, Gil-Gil, Miguel, additional, Pernas, Sonia, additional, Gonzalez-Suarez, Eva, additional, and Falo, Catalina, additional

Published
2022
Full Text
View/download PDF

18. Abstract P5-07-06: Genomic characterization and tumor evolution in matched(primary-relapse)samplesof patients with METAPLASTIC breast cancer

Author

Cejuela, Mónica, primary, Stradella, Agostina, additional, Petit, Anna, additional, Gargallo, Pablo, additional, Bosch, Jan, additional, Carbonell, Paula, additional, Recalde, Sabela, additional, Vethencourt, Andrea, additional, Fernández, Adela, additional, Falo, Catalina, additional, Gil-Gil, Miguel, additional, Vazquez, Silvia, additional, Villanueva, Rafael, additional, Soler, Teresa, additional, Calabria, Inés, additional, and Pernas, Sonia, additional

Published
2022
Full Text
View/download PDF

19. RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and a therapeutic target in patient-derived xenografts

Author

Ciscar, Marina, primary, Trinidad, Eva M, additional, Perez-Montoyo, Hector, additional, Alsaleem, Mansour, additional, Jimenez-Santos, Maria J, additional, Toss, Michael, additional, Sanz-Moreno, Adrian, additional, Vethencourt, Andrea, additional, Perez-Chacon, Gema, additional, Petit, Anna, additional, Soler-Monso, Maria T, additional, Gomez-Miragaya, Jorge, additional, Gomez-Aleza, Clara, additional, Jimenez, Maria, additional, Dobrolecki, Lacey E, additional, Lewis, Michael T, additional, Bruna, Alejandra, additional, Mouron, Silvana, additional, Quintela-Fandino, Miguel, additional, Alshahrour, Fatima, additional, Martinez-Aranda, Antonio, additional, Sierra, Angels, additional, Green, Andrew R, additional, Rakha, Emad, additional, and Gonzalez-Suarez, Eva, additional

Published
2021
Full Text
View/download PDF

21. Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.

Author

Fullana B, Morales S, Petit A, Alay A, Verdaguer H, Climent F, Navarro-Perez V, Cejuela M, Galvan P, Gumà A, Llombart-Cussac A, Cordero D, Casanovas O, Prat A, Gil-Gil M, and Pernas S

Subjects
Humans, Female, Aged, Middle Aged, Neoplasm Staging, Receptors, Progesterone metabolism, Aged, 80 and over, Treatment Outcome, Biomarkers, Tumor metabolism, Sunitinib therapeutic use, Sunitinib administration & dosage, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Breast Neoplasms pathology, Androstadienes administration & dosage, Androstadienes therapeutic use, Androstadienes adverse effects, Postmenopause, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Receptor, ErbB-2 metabolism, Receptor, ErbB-2 genetics, Neoadjuvant Therapy, Receptors, Estrogen metabolism
Abstract

Neoadjuvant endocrine therapy (NET) for hormone receptor-positive (HR+) breast cancer might be as effective as chemotherapy, with a better toxicity profile. Blocking a crucial process such as angiogenesis with sunitinib may have a synergistic effect with NET. We aimed to assess the efficacy and safety of neoadjuvant sunitinib plus exemestane in early-stage HR+/HER2-negative breast cancer. In this phase I/II study, postmenopausal women with HR+/HER2- stage II-III breast cancer received neoadjuvant exemestane at conventional dose of 25mg plus sunitinib in a 3 + 3 design at 25mg (3/1weeks scheme) or 37.5mg continuous dose, for 6 months. Coprimary endpoints were the recommended dose of sunitinib combined with exemestane and objective response. Secondary endpoints included safety and biomarkers of early response. For 15 months, 18 patients were enrolled, 15 at sunitinib 25mg and 3 at 37.5mg. Median age was 73, 77% of patients had T2 tumors and 67% node-positive disease. The most common grade 2 toxicity was asthenia (44%), as was hypertension (22%) for grade 3. No grade 4-5 were reported. Twelve patients (66%) achieved an objective response. VEGFR-2 levels significantly decreased after one month of treatment. Differential gene expression analysis showed downregulation of ESR1, PGR and NAT1 in post-treatment samples and upregulation of EGFR, MYC, SFRP1, and FOXC1. PAM50 analysis on 83% of patients showed a prevalence of luminal A subtype, both in pre-treatment (63.6%) and post-treatment tumors (54.5%). Sunitinib plus exemestane was associated with substantial yet reversible toxicities, providing safety, efficacy and biological impact insights of combining an antiangiogenic drug with hormone therapy in early-stage breast cancer.Trial registration: Registered with ClinicalTrials.gov, NCT00931450. 02/07/2009., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results